JPMorgan Chase & Co. Reaffirms "Underweight" Rating for GSK (LON:GSK)

GSK (LON:GSK - Get Free Report)'s stock had its "underweight" rating reissued by equities research analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Friday, Marketbeat Ratings reports.

Separately, Berenberg Bank lowered their price target on GSK from GBX 1,820 ($23.51) to GBX 1,600 ($20.67) and set a "buy" rating on the stock in a research report on Friday, November 29th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, GSK currently has a consensus rating of "Moderate Buy" and an average target price of GBX 1,805.83 ($23.33).

GSK Trading Up 0.5 %

GSK traded up GBX 7 ($0.09) during trading on Friday, reaching GBX 1,469 ($18.98). The company had a trading volume of 8,888,438 shares, compared to its average volume of 18,070,469. The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81. The company has a market cap of £59.61 billion, a price-to-earnings ratio of 23.73, a PEG ratio of 1.24 and a beta of 0.31. GSK has a 12-month low of GBX 1,282.50 ($16.57) and a 12-month high of GBX 1,823.50 ($23.56). The firm's 50-day simple moving average is GBX 1,458.19 and its 200 day simple moving average is GBX 1,431.63.

GSK (LON:GSK - Get Free Report) last announced its earnings results on Wednesday, February 5th. The company reported GBX 23.20 ($0.30) earnings per share (EPS) for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Equities research analysts anticipate that GSK will post 175.980975 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Wendy Becker purchased 536 shares of GSK stock in a transaction that occurred on Thursday, March 20th. The shares were acquired at an average price of GBX 1,515 ($19.57) per share, for a total transaction of £8,120.40 ($10,491.47). Also, insider Emma Walmsley sold 38,459 shares of the firm's stock in a transaction dated Monday, February 17th. The shares were sold at an average price of GBX 1,418 ($18.32), for a total transaction of £545,348.62 ($704,584.78). Corporate insiders own 1.61% of the company's stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.